bg-tumor-monitoring

1 Tube, 1 Week, Complete Results

DNA, RNA, MSI, Immunotherapy. Somatic and Hereditary. Blood, Tissue, Buccal.

Your genes, right now.

CIRCULOGENE’s molecular diagnostics process is based on the discovery that as tumor cells multiply, they also die, releasing their DNA into the bloodstream. CIRCULOGENE’s comprehensive tumor DNA sequencing is the only testing available that combines minimal volumes of blood with the most advanced next-generation sequencing (NGS) to monitor tumor-mutant DNA within well-characterized, well-documented, cancer-associated genes.

With just one tube of blood, CIRCULOGENE’s patented technology utilizes NGS to monitor thousands of known tumor mutations across multiple cancer-associated genes, providing the most comprehensive information on current FDA-approved treatment options.

Access

Minimal-volume input with maximal yield. One tube for the full range of DNA, RNA, and MSI immunotherapy testing means access to a patient’s blood is even less invasive.

Enrich

Proprietary, direct-on-specimen enrichment technology locates and captures cell-free DNA, identifying and quantifying any tumor mutations for accurate reporting and monitoring.

Detect

Capable of testing more than 50 genes for approximately 3,000 possible mutations. Multi-mutation monitoring capabilities encompass a broad range of tumor profiles and allow for rapid-turnaround, patient-centered, precision medicine.

The CIRCULOGENE Advantage

Because our patented technique enriches the sample, CIRCULOGENE analysis only requires only one tube of blood, which is more convenient for health care professionals and patients.
CIRCULOGENE’s tests analyze for the presence of cell-free DNA, identifying and quantifying any tumor mutations for accurate reporting and monitoring.
In our personalized gene reports, CIRCULOGENE further provides information on current FDA-approved treatment options proven effective for the tumor DNA mutations identified.
The efficiency of CIRCULOGENE’s process empowers physicians to closely monitor tumor responsiveness and adjust treatment protocols. Turnaround time is five to seven days, much faster than tissue biopsy results and other liquid biopsies.
The CIRCULOGENE process uses precise baseline data from which to measure cell turnover and progression.
We compared the sensitivity of our proprietary cell-free DNA enrichment method to the standard DNA extraction kit used industry-wide today. Results demonstrated 100x more cell-free tumor DNA in the original sample using a single tube of blood.
Clinical Laboratory Improvement Amendments (CLIA)
Certificate of Compliance
CIRCULOGENE
3125 Independence Drive, Suite 301
CLIA ID NUMBER: 01D2101075

Downloads

Sample Report
Sample Report Overview

Requisition Forms

Hereditary/Somatic Requisition
Tissue Requisition
Hereditary Requisition
Genetic Consent

Contact Us

3125 Independence Drive
Suite 301
Birmingham, AL 35209

855-614-7083

info@circulogene.com